← Eichor
Condition: Nimotuzumab Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nimotuzumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
Phase 2 · 1 location(s) · Zhejiang Provincial People's Hospital · NCT06722911Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Phase 3 · 1 location(s) · Biotech Pharmaceutical Co., Ltd. · NCT05978050Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant R
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06259721Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06410651Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Phase 1/Phase 2 · 1 location(s) · University of Saskatchewan · NCT04459065Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr
Phase 2 · 6 location(s) · Ming-Yuan Chen · NCT07070479Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cyc
Phase 3 · 1 location(s) · Fudan University · NCT05772208Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06718205Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Ve
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07706985Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
NA · 9 location(s) · Fourth Affiliated Hospital of Guangxi Medical University · NCT05717790GNT Induction Treatment in Locally Advanced NPC
Phase 3 · 1 location(s) · Air Force Military Medical University, China · NCT06026878Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06988956SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After
Phase 2 · 2 location(s) · The First Affiliated Hospital of Xiamen University · NCT06676722Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Phase 2 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06389760HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Phase 2 · 2 location(s) · Zhejiang University · NCT07240766Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva
Phase 3 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT07333274Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)
Phase 1/Phase 2 · 1 location(s) · University of Saskatchewan · NCT04235114Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06429839Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06509009Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cel
Phase 2 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07601737TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06912711A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous C
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT07105592Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck
Phase 3 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT07445048Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07457528Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
NA · 1 location(s) · Gansu Wuwei Tumor Hospital · NCT06840067Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07101744Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07353723HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Phase 2 · 2 location(s) · Zhejiang University · NCT06770452
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.